The preventive effect of Ninjin'yoeito on sarcopenia among patients with advanced urotherial carcinoma
Phase 2
Recruiting
- Conditions
- Advanced urothelial carcinoma, Sarcopenia
- Registration Number
- JPRN-jRCTs021210048
- Lead Sponsor
- Okamoto Teppei
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
1. Patients with advanced urothelial carcinoma who recieve platinum-based chemotherapy (Age; 65-90 years)
2. Patients who understand and are willing to participate this study.
3. Patients without a severe general condition due to progressive disease.
4. Patients without an abnormality in liver function and serum potassium level.
5. Patients who do not take other harbal medicines which have supportive roles for cancer treatment.
Exclusion Criteria
1. Patients can not take a harbal medicine due to dysphagia and/or tube feeding.
2. Patients who have already took other harbal medicines which have supportive roles for cancer treatment.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To compare the change rates of psoas muscle area of study participants with those of historical cohort 8 weeks after the study commencement
- Secondary Outcome Measures
Name Time Method The evaluation of change in frailty, body composition, and serum grelin levels 4 and 8 weeks after the study.